Disease of uterus/ovary Laparoscopic hysterectomy Postoperative opioid consumption Multimodal analgesia Nefopam Nefopam Laparoscopic hysterectomy Postoperative opioid consumption Postoperative pain control
Conditions
Interventions
Nefopam 20 mg IV drip in 60 minutes at 1 hour before ending operation,NSS 100 ml IV drip in 60 minutes at 1 hour before ending operation
Experimental Drug,Placebo Comparator Other
Nefopam IV drip,NSS IV drip
Sponsors
Faculty of Medicine, Prince of Songkla University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. age 18-65 2. ASA classification 1-3 3. Patients were scheduled for Laparoscopic Hysterectomy 4. Elective surgery
Exclusion criteria
Exclusion criteria: 1. Allergy or Drug Sensitivity to drugs being used in the investigation (paracetamol, bupivacaine, nefopam, dynastat, opioids), sulfonamide 2. Severe cardiovascular diseases (Congestive heart failure NYHAII-IV, post CABG, established ischemic heart disease) 3. Peripheral arterial disease 4. Bleeding disorder, coagulopathy, on anticoagulants (warfarin) 5. Neurological disorders, cerebrovascular disease, history of convulsion 6. Severe hepatic impairment (serum albumin<25g/L, or Child-Pugh score>=10) 7. Severe renal impairment (GFR<30mL/min/1.73m2) 8. Asthma, urticaria, or allergic type reaction after taking aspirin, NSAIDs or other COX-2 specific inhibitors. 9. Angle-closure glaucoma 10. Concomitant use with MAOIs, fluconazole, diuretics, cyclosporine, methotrexate, lithium opioid derivatives (analgesics, anti-cough products and substitutive treatment), neuroleptics, barbiturates, benzodiazepine, anxiolytics other than benzodiazepines, hypnotics, sedative antidepressants (TCAs, SSRIs and SNRI), sedative antihistaminic H1, central antihypertensive drugs, baclofen and thalidomide 11. Who have inflammatory bowel disease, ulcer, bleeding or perforation of gastrointestinal tract 12. Pre-existing chronic pain conditions requiring regular pain medication. 13. Individuals with psychiatric disorders that impair the ability to provide informed consent or comply with study procedures. 14. Pregnancy and Lactation 15. Body mass index >40 kg/m2 16. Concomitant use of tramadol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative morphine consumption 6, 12, 18, 24 PCA morphine | — |
Secondary
| Measure | Time frame |
|---|---|
| Numerical rating scale pain score 6, 12, 18, 24 NRS pain score | — |
Countries
Thailand
Contacts
Public ContactMaliwan Oofuvong
Faculty of Medicine, Prince of Songkla University
Outcome results
None listed